Zomedica Corp. provided revenue guidance for the fourth quarter and full year of 2023. Revenue for the fourth quarter of 2023 is expected to be over $7 million, a new record for the Company, compared to record fourth quarter 2022 revenue of $6.2 million.

Revenue for 2023 is expected to be over $25 million, an increase of over 32% compared to 2022 revenue of $18.9 million.

For the full year 2024, the Company is introducing formal financial guidance, as follows: the Company expects full year revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of over $25 million.